Avenue Therapeutics, Inc.

NasdaqCM ATXI

Avenue Therapeutics, Inc. Share Price on January 14, 2025: USD 1.88

Avenue Therapeutics, Inc. Share Price is USD 1.88 on January 14, 2025, a -83.81% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Avenue Therapeutics, Inc. 52-week high Share Price is USD 14.40 on March 08, 2024, which is 665.96% above the current Share Price.
Avenue Therapeutics, Inc. 52-week low Share Price is USD 1.66 on December 17, 2024, which is -11.70% below the current Share Price.
Avenue Therapeutics, Inc. average Share Price for the last 52 weeks is USD 5.12.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqCM: ATXI

Avenue Therapeutics, Inc.

CEO	Dr. Alexandra MacLean M.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	1140 Avenue of the America
Employees	3
Sector	Health Care
Industries Pharmaceuticals

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years